In a Washington Post opinion piece, former Trump FDA chief Dr. Scott Gottlieb argues the “CBD craze is getting out of hand. The FDA needs to act.”
- Gottlieb, a relative CBD skeptic, says “The FDA can fulfill its public-health obligations and meet the political demand for these goods: It can approve the sale of some CBD products immediately, while effecting a framework for their safe and proper regulation and a pathway for an enforceable market for these goods.
- He says the risks of CBD are, “It can cause damage to the liver at high doses, and it may have a cumulative effect. If you eat CBD in your breakfast, lunch and dinner, you could get a toxic dose. Currently marketed products might also have undeclared ingredients and impurities,” including THC.
Meanwhile, a venture between pharma giants Pfizer and GlaxoSmithKline is investigating CBD.
- “The science is young in the space, but we realize it’s something consumers are using in their repertoire, so we are looking into it,” the venture’s CEO said.
- The DEA is under pressure to explain why no federal research permits to grow MED have been granted since 2016.